Immunoadsorption in Dermatology

Damian Meyersburg*, Enno Schmidt, Michael Kasperkiewicz, Detlef Zillikens

*Korrespondierende/r Autor/-in für diese Arbeit
25 Zitate (Scopus)

Abstract

Immunoadsorption (IA) has been successfully used in a large variety of autoantibody-mediated disorders. In dermatology, IA is increasingly applied as adjuvant treatment for severe and/or refractory autoimmune bullous diseases. These disorders are characterized by autoantibodies against structural proteins of the skin and/or mucous membranes and include, among others, pemphigus vulgaris, pemphigus foliaceus, and bullous pemphigoid. Autoimmune blistering diseases are associated with a high mortality (pemphigus) or morbidity (bullous pemphigoid) and in particular in pemphigus diseases, treatment is challenging. The pathogenetic role of autoantibodies in most of the immunobullous diseases has been clearly demonstrated, therefore, removal of these autoantibodies is a rational therapeutic approach. IA has been shown to effectively lower the serum autoantibodies and to lead to rapid clinical responses. Most recently, IA has been successfully applied in patients with severe atopic dermatitis and high total serum IgE levels. Here, the different treatment protocols, clinical efficacy, and adverse events are summarized.
OriginalspracheEnglisch
ZeitschriftTherapeutic Apheresis and Dialysis
Jahrgang16
Ausgabenummer4
Seiten (von - bis)311-320
Seitenumfang10
ISSN1744-9979
DOIs
PublikationsstatusVeröffentlicht - 01.08.2012

Fingerprint

Untersuchen Sie die Forschungsthemen von „Immunoadsorption in Dermatology“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren